SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-022324
Filing Date
2022-11-07
Accepted
2022-11-07 07:33:07
Documents
81
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q verv-20220930.htm   iXBRL 10-Q 3831298
2 EX-10.2 verv-ex10_2.htm EX-10.2 1433085
3 EX-10.3 verv-ex10_3.htm EX-10.3 1176944
4 EX-31.1 verv-ex31_1.htm EX-31.1 20231
5 EX-31.2 verv-ex31_2.htm EX-31.2 20383
6 EX-32.1 verv-ex32_1.htm EX-32.1 12350
7 EX-32.2 verv-ex32_2.htm EX-32.2 12322
  Complete submission text file 0000950170-22-022324.txt   14449423

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT verv-20220930_def.xml EX-101.DEF 293010
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT verv-20220930_lab.xml EX-101.LAB 548177
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT verv-20220930_cal.xml EX-101.CAL 45536
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT verv-20220930.xsd EX-101.SCH 74115
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT verv-20220930_pre.xml EX-101.PRE 444005
75 EXTRACTED XBRL INSTANCE DOCUMENT verv-20220930_htm.xml XML 1987691
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40489 | Film No.: 221363745
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences